Revance Therapeutics Inc (NASDAQ:RVNC)
| 30.46 Delayed Data As of May 26 |  -0.35 / -1.14%Today’s Change | 11.27 Today|||52-Week Range 37.98 | +65.01% Year-to-Date |
Five Year Financial Summary
| All Currency in US Dollars | 4 Quarter Trend | |||||
|---|---|---|---|---|---|---|
| Quarter 3 2018 | Quarter 4 2018 | Quarter 1 2019 | Quarter 2 2019 | |||
| Revenue and Income | Net Revenues | 2.4M | 487.0K | 278.0K | 0.00 | |
| Depreciation And Amortization | 444.0K | 475.0K | 628.0K | 790.0K | ||
| Operating Expenses | Gross Income | -- | -- | -- | -790.0K | |
| General Expenses | 35.6M | 38.4M | 36.3M | 38.3M | ||
| Research And Development | 21.8M | 25.5M | 24.0M | 25.5M | ||
| Total Operating Expenses | 36.0M | 38.9M | 36.9M | 39.1M | ||
| Non-Operating Expenses | Operating Income | -33.6M | -38.4M | -36.6M | -39.1M | |
| Extraordinary Credit | 0.00 | 10.0K | -- | 21.0K | ||
| Extraordinary Charge | -45.0K | 0.00 | -92.0K | 0.00 | ||
| Other Expenses | -144.0K | -147.0K | -155.0K | 115.0K | ||
| Income Taxes, Minority Interest and Extra Items | Pre-Tax Income | -32.8M | -37.6M | -35.3M | -37.4M | |
| Income Taxes | 0.00 | -3.0M | 0.00 | 0.00 | ||
| Net Income | -32.8M | -40.6M | -35.3M | -37.4M | ||
| Shares To Calculate EPS | Shares To Calculate EPS | 36.3M | 36.3M | 41.6M | 43.3M | |
| Shares To Calculate EPS Diluted | 36.3M | 36.3M | 41.6M | 43.3M | ||
| Earnings Per Share | EPS | -$0.91 | -$1.12 | -$0.85 | -$0.86 | |
| EPS Diluted | -$0.91 | -$1.12 | -$0.85 | -$0.86 | ||
